You've Stopped Taking Wegovy — Here's What to Expect

The morning you noticed your appetite was back

Many people describe the same thing: a few weeks after their last Wegovy dose, hunger starts to feel different. The easy fullness that made portion control almost effortless begins to fade. Food thoughts return with an intensity that feels oddly familiar. This is not imagination. Semaglutide works by activating GLP-1 receptors in the brain and gut, slowing stomach emptying and reducing appetite signals. Once the medicine clears your system (semaglutide has a half-life of roughly a week, so it takes several weeks to wash out fully) those receptors return to their baseline state.

The STEP 1 trial, published in the New England Journal of Medicine, followed participants after they stopped semaglutide 2.4mg at 68 weeks. Within a year of discontinuation, most had regained around two-thirds of the weight they had lost. That figure is striking, but the researchers were clear: it points to weight management as an ongoing condition rather than a problem that a fixed course of medicine permanently solves.

Understanding this biology matters because it changes how you think about what stopping means, and what your realistic options are, including how taking Wegovy correctly from the start can influence how well your body responds over time.

Why people stop, and whether the reason changes what comes next

There are lots of reasons someone might have stopped. Side effects (especially the nausea, constipation or reflux that tend to peak after a dose increase) push some people to pause treatment before their body has had time to settle. Others stop because of cost pressures, supply disruptions, a planned surgery (your anaesthetist needs to know if you are on a GLP-1 medicine, as NHS England's guidance on weight-management injections makes clear), or pregnancy. Some stop simply because they have reached a target weight and assumed the job was done.

The reason matters because it shapes the path forward. If you stopped because of side effects, a slower titration (starting again from the lowest dose and spending longer at each step) can make a significant difference. If you stopped due to cost, it is worth understanding what a full private prescription actually includes, because treatment feeling less effective over time is sometimes down to gaps in supply or dosing rather than the medicine itself. If you stopped because you felt well and assumed you no longer needed it, the evidence above is worth sitting with.

If Wegovy appeared to stop working before you discontinued, that is a separate but related question, and a plateau on Wegovy sometimes reflects a dose that needs reviewing rather than treatment failure.

What a gap of a month or more actually does

A short interruption of a few days is unlikely to cause significant weight regain. A gap of a month is a different matter. By that point the medicine has largely cleared, appetite regulation has shifted back towards your pre-treatment baseline, and the habits you built during treatment can feel harder to maintain without the biological assist semaglutide was providing.

If you have been off treatment for around a month, the practical reality is that restarting is usually not as simple as picking up where you left off. Most prescribers will want to reassess your current weight and health before approving a restart, and many will recommend returning to a lower starting dose rather than jumping back to the dose you were on. This reduces the chance that side effects hit harder than they did the first time. The considerations specific to a month-long break are worth reading if that describes your situation.

One practical detail: if you have stored an unused pen in the fridge and are wondering whether it is still viable, always check the expiry date on the pen itself and follow the storage guidance in the Patient Information Leaflet rather than relying on memory of when you bought it.

Thinking about what comes next

Weight management after stopping Wegovy tends to go better for people who have a plan rather than those who simply wait to see what happens. That plan usually involves three things: honest monitoring of weight over the weeks after stopping; keeping up the dietary and activity habits that worked alongside treatment; and a clear decision point (agreed in advance with a prescriber) at which restarting treatment would be considered.

For some people, stopping is absolutely the right outcome: they have reached and consolidated a healthier weight, their comorbidities have improved, and they are managing well. The NHS semaglutide guidance notes that continuing treatment is reviewed if the expected benefit is not being maintained. That review should happen with a clinician, not alone.

If you are weighing up the economics alongside the clinical picture, understanding what a private prescription actually covers is part of that conversation, the weight loss treatment options at nume set out what is included in a transparent single price, with no subscription and a fresh clinical review before every repeat.

Anyone who has stopped losing weight on Wegovy before deciding to discontinue should also consider whether dose optimisation was explored before stopping, that conversation is best had with a prescriber rather than based on online accounts of other people's experience, which vary enormously.

Our prescribers at nume's clinical team review consultations the same day, seven days a week, and can help you think through whether restarting, switching, or a different approach makes sense for you. There is no obligation in starting that conversation.